Address And Details

500 Boylston St , Boston, MA 02116
Fund Manager Philipp Burgener
Manager Tenure 4 Years 7 Months

Strategy And Objective

The fund’s investment objective is to seek total return with an emphasis on current income, but also considering capital preservation. The fund’s objective may be changed without shareholder approval. MFS normally invests the fund’s assets primarily in debt instruments. The fund’s dollar-weighted average effective maturity will normally not exceed five years. In determining an instrument’s effective maturity, MFS uses the instrument’s stated maturity or, if applicable, an earlier date on which MFS believes it is probable that a maturity-shortening device (such as a call, put, pre-refunding, prepayment or redemption provision, or an adjustable coupon) will cause the instrument to be repaid. Such an earlier date can be substantially shorter than the instrument’s stated maturity.

Net Asset Value

as of 5:48 PM ET 09/24/2021


  • 1 Week
  • -0.16%
  • 1 Month
  • -0.16%
  • 3 Months
  • -0.33%
  • 1 Yr Return
  • -0.66%
  • 5 Yr Return
  • +0.83%

Equity Sector Breakdown

ConsumerDurables n/a
Energy n/a
Finance n/a
Health n/a
IndustrialCyclical n/a
NonDurables n/a
RetailTrade n/a
Services n/a
Technology n/a
Utilities n/a

Asset Allocation

Asset Type % Of Allocation
Bonds 95.96%
Cash 3.91%
Other 0.14%
Stocks 0.00%
Preferred 0.00%
Convertible 0.00%
ForeignStocks 0.00%
ForeignBonds 0.00%
ForeignHedged 0.00%
Total Net Assets 38.38 M

Risk Measures

Criteria 3 Years 5 Years 10 Years
Alpha -0.29 -0.37 -0.39
Beta 0.37 0.33 0.27
R Squared 0.20 0.22 0.22
Std Deviation 2.86 2.27 1.72
Sharpe Ratio 0.46 0.13 n/a

Purchase Information

as of 5:44 PM ET 09/16/2021
Minimum Initial $1000
Minimum Additional $50
Minimum Initial IRA $250


Timeframe Average Annual Current Performance Monthly As Of 08/31/2021 Average Annual Current Performance Quarterly As Of 05/31/2021 Avg Annual Current Performance Monthly As Of 08/31/2021 Avg Annual Current Performance Quarterly As Of 05/31/2021
1 Year
  • +0.52%
  • +2.81%
+0.52% +2.81%
3 Year
  • +2.40%
  • +2.59%
+2.40% +2.59%
10 Year
  • +0.92%
  • +0.90%
+0.92% +0.90%
Life Of Fund
  • +2.61%
  • +2.65%
+2.61% +2.65%

Top 10 Holdings

Symbol Company Name % Of Assets

Recent Articles from TheStreet

wynn resorts broll

Jim Cramer Talks Macao With Wynn Resorts CEO

Matthew Maddox argues China's crackdown will lead to better regulation.

Tesla Lead

Electric Vehicle Checkpoint: Experts Say EV Revolution is Here

See the latest news for the top stocks in the electric vehicle space including Tesla, Ford, General Motors, Li Auto and more.


Tim Collins on How to Trade Nikola

Technical setups and short interest make much hated name volatile, and therefore interesting.

Chinese Firms Should Face Faster US Stock Delisting Over Audit Rules, SEC Chairman Gary Gensler Tells Lawmakers

Jim Cramer: Gensler's Plate is Very Full

SEC Chairman is key player in efforts to rein in ceaseless financial engineering.

stocks rise asset management sh

Cramer's Mad Money Recap: Advanced Micro Devices, Nvidia, Thor

Jim Cramer has your game plan for next week, which he says will be the calm before the earnings season storm.

Jim Cramer: Starbucks Needs More Traffic in Stores

Starbucks Resists Union Effort in New York Region: Report

Starbucks reportedly said it will raise wages and benefits and a union isn’t needed, to employees at three stores in Buffalo New York.

Exxon Mobil

Exxon, Occidental, Baker Hughes Make Goldman Turnaround List

Exxon has 'reduced costs, surprised to the downside on capital spending, outperformed our expectations in downstream/chemicals,' Goldman said.


Jim Cramer is Tired of the Weak Response to Chip Shortages

Companies need to forget about help from Washington and step up to the plate.

Microsoft Lead

Why 'Sarge' Guilfoyle Isn't Selling His Microsoft

Sharp management and strength across its business lines are keys to software giant.

Why Charles River Labs Is the Biotech Stock to Buy: Jim Cramer

Bret Jensen: Paratek Deal Shows Promise

While antibiotics are usually less profitable and slower to develop market share than other drugs, Paratek has a key factor in its favor.